{
    "nctId": "NCT00065533",
    "briefTitle": "Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer",
    "officialTitle": "Study of Two Doses of ALIMTA (Pemetrexed) as First Line Chemotherapy for Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 92,
    "primaryOutcomeMeasure": "To assess tumor response.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Be at least 18 years of old.\n* Have been diagnosed with breast cancer\n* At least one year disease-free interval after initial treatment.\n* Have pre-study laboratory tests that are within the requirements of this study.\n* Be able to visit the doctor's office weekly during the treatment period.\n\nExclusion Criteria:\n\n* To be pregnant or breastfeeding.\n* To be currently taking aspirin or aspirin- like medicine and unable to stop for a few days during each cycle of therapy.\n* To have received prior chemotherapy for the treatment of metastatic cancer. Patients may have received prior hormonal treatment.\n* To have another illness that your doctor thinks would make you unable to participate.\n* To be unable or not willing to take folic acid and vitamin B12.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}